Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies

J Clin Oncol. 2016 Apr 20;34(12):1428-9. doi: 10.1200/JCO.2015.66.4201. Epub 2016 Feb 16.

Authors

Matthew C Cheung¹, Mona Sabharwal², Alexandra Chambers², Dolly Han², Kelley-Anne Sabarre², Kelvin Chan³

Affiliations

¹ Canadian Agency for Drugs and Technology in Health, Sunnybrook Health Sciences Centre, and University of Toronto, Toronto, Ontario, Canada matthew.cheung@sunnybrook.ca.
² Canadian Agency for Drugs and Technology in Health, Toronto, Ontario, Canada.
³ Canadian Agency for Drugs and Technology in Health, Sunnybrook Health Sciences Centre, Canadian Centre for Applied Research in Cancer Control, and University of Toronto, Toronto, Ontario, Canada.

PMID: 26884567
DOI: 10.1200/JCO.2015.66.4201

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / economics*
Antineoplastic Agents / therapeutic use*
Cost-Benefit Analysis
Decision Support Techniques
Drug Costs*
Drugs, Investigational / adverse effects
Drugs, Investigational / economics*
Drugs, Investigational / therapeutic use*
Humans
Models, Economic
Neoplasms / drug therapy*
Neoplasms / economics*
Patient Selection
Quality of Life
Treatment Outcome

Substances

Antineoplastic Agents
Drugs, Investigational